Harrow Inc - Company Profile
Powered by 
All the sales intelligence you need on Harrow Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Harrow Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Harrow Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Harrow Inc (Harrow) is a leading pharmaceutical company specializing in the ophthalmic healthcare sector. The company's primary activities involve the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products. Harrow's product portfolio includes a wide range of FDA-approved prescription and non-prescription pharmaceuticals for treating various eye conditions, such as dry eye disease, allergies, infections, glaucoma, and other ophthalmic inflammatory conditions. The company markets its products under the Harrow name and also operates ImprimisRx, a leading ophthalmology-focused pharmaceutical-compounding business. Harrow's products are used by doctors, hospitals, and ambulatory surgical centers (ASCs) across various industries. The company operates across the US. Harrow is headquartered in Nashville, Tennessee, the US.
Headquarters
United States of America
Address
1a Burton Hills Blvd, Suite 200, Nashville, Tennessee, 37215
Website
www.harrow.com
Telephone
1 615 7334730
No of Employees
373
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
HROW (NASD)
Revenue (2024)
$272.3M
36.4%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
70.6%
(2024 vs 2023)
Market Cap*
$1.5B
Net Profit Margin (2024)
XYZ
78.4%
(2024 vs 2023)
* As of and is in US$
Harrow Inc premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Iheezo | Pharmaceutical Compounding |
| Iopidine | Pharmaceutical Drug Development |
| Freshkote eye drops | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Acquisitions/Mergers/Takeovers | In November, the company acquired Melt Pharmaceuticals, Inc, a pharma company. |
| 2025 | Corporate Changes/Expansions | In September, the company expands Harrow Access for All (“HAFA”) an Innovative Market Access Model Across Ophthalmic Portfolio. |
| 2025 | Contracts/Agreements | In July, the company enter into commercialization agreement with with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States. |
Competitor Comparison
| Key Parameters | Harrow Inc | Amneal Pharmaceuticals Inc | EyePoint Inc | Casper Pharma LLC | Chethana Pharmaceuticals |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | India |
| City | Nashville | Bridgewater | Watertown | East Brunswick | Malappuram |
| State/Province | Tennessee | New Jersey | Massachusetts | New Jersey | Kerala |
| No. of Employees | 373 | 8,500 | 214 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mark L. Baum | Chairman; Chief Executive Officer | Executive Board | 2011 | 53 |
| Andrew R. Boll | Secretary; Chief Financial Officer | Senior Management | 2015 | 43 |
| Amir H. Shojaei, PhD | Chief Scientific Officer | Senior Management | 2025 | 58 |
| John P. Saharek | Chief Commercial Officer; President - ImprimisRx | Senior Management | 2019 | 64 |
| Kim Barratt | Chief Talent Officer | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer